Last day of trading in warrants series TO 13 in Alligator Bioscience is 11 September 2025
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator announces publication in Cancer Immunology Research of preclinical data on ATOR-4066, a tumor-directed CD40×CEACAM5 bispecific antibody
Lund, Sweden – 10 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develo ...
Alligator Bioscience has renegotiated the outstanding loan from Fenja Capital and received subscription intentions from members of the Board of Directors and management
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Grant awarded to investigator-initiated Phase 2/3 trial with mitazalimab in biliary tract cancer
Lund, Sweden – 8 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develop ...
Alligator announces evaluation and option agreement covering RUBY™ antibody format
Lund, Sweden – 2 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Alligator has entered into ...
Exercise price determined for the exercise of warrants series TO 13 in Alligator Bioscience AB
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience provides highlights from R&D event 2025
Lund, Sweden – 20 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...
Alligator Bioscience announces upcoming presentation of REACtiVe-2 Phase 1 data at ESMO Congress 2025
Lund, Sweden – 25 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...
Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer
Lund, Sweden – 14 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today comments on the announcement by Shanghai Henl ...